Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 875

1.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
2.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

Br J Dermatol. 2006 Jun;154(6):1161-8.

PMID:
16704649
3.

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.

Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.

Br J Dermatol. 2008 Sep;159(3):704-10. doi: 10.1111/j.1365-2133.2008.08727.x. Epub 2008 Jul 9.

PMID:
18627375
4.

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A.

J Am Acad Dermatol. 2004 Oct;51(4):534-42.

PMID:
15389187
5.

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.

Torii H, Nakagawa H; Japanese Infliximab Study investigators.

J Dermatol Sci. 2010 Jul;59(1):40-9. doi: 10.1016/j.jdermsci.2010.04.014. Epub 2010 May 4.

PMID:
20547039
6.

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.

Arthritis Rheum. 2005 Apr;52(4):1227-36. Erratum in: Arthritis Rheum. 2005 Sep;52(9):2951.

7.

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE.

Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. Epub 2007 Aug 2.

PMID:
17673380
8.

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

Br J Dermatol. 2005 Dec;153(6):1192-9.

PMID:
16307657
9.

Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.

Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.

Br J Dermatol. 2010 May;162(5):1117-23. doi: 10.1111/j.1365-2133.2009.09578.x. Epub 2009 Nov 10.

PMID:
19906069
10.

Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.

Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI; PEARL investigators.

J Drugs Dermatol. 2012 Aug;11(8):943-9.

PMID:
22859239
11.
12.

A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.

Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.

Br J Dermatol. 2007 Feb;156(2):329-36.

PMID:
17223874
13.

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.

J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15. Epub 2006 Sep 6.

PMID:
17097378
14.

Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.

Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, Wang BX, Zhang FR, Li CY, Liu XM, Tu CX, Ji SZ, Shen Y, Zhu XJ.

Chin Med J (Engl). 2012 Jun;125(11):1845-51.

PMID:
22884040
15.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
16.

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.

Dermatology. 2009;219(3):239-49. doi: 10.1159/000237871. Epub 2009 Sep 10.

PMID:
19752505
17.

Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.

Salim A, Tan E, Ilchyshyn A, Berth-Jones J.

Br J Dermatol. 2006 Jun;154(6):1169-74.

PMID:
16704650
18.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
19.

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.

Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9.

PMID:
19903183
20.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

Supplemental Content

Support Center